Next-generation sequencing is the process of sequencing DNA strands similar to the nucleotides in a DNA molecule. Next-generation sequencing is carried by massive parallelization. Next-generation sequencing reduces the requirements for the fragment-cloning method used in sequencing of the genomes by Sanger’s method. Due to high accuracy, precise results, and low cost, and with low sample, next-generation sequencing is preferred over the Sanger’s method. It is commonly used in oncology studies, biomarker discovery, agricultural and animal research, personalized medicine, and others. In addition, re-sequencing of targets, identification of binding sites of a transcriptional factor, and non-coding RNA expression profiling are other applications of next-generation sequencing.
Some of the players in global next-generation sequencing market are:
Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Pacific Biosciences (Danaher Corporation) (U.S.), Thermo Fisher Scientific Inc. (U.S.), Qiagen N. V. (Germany), Beijing Genomics Institute (China), PerkinElmer, Inc (U.S.), F. Hoffmann La Roche AG (Switzerland), Genomatix GmbH (Germany), Oxford Nanopore Technologies (U.K.), and Eurofins Scientific (U.S.) to name a few.
No comments:
Post a Comment